Edurant Ped Patent Expiration

Edurant Ped is a drug owned by Janssen Products Lp. It is protected by 2 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 23, 2037. Details of Edurant Ped's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 HIV inhibiting pyrimidines derivatives
Apr, 2025

(9 months from now)

Active
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065198 Dispersible compositions
Oct, 2037

(13 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Edurant Ped's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Edurant Ped's generic, the next section provides detailed information on ongoing and past EP oppositions related to Edurant Ped patents.

Edurant Ped's oppositions filed in EPO

Edurant Ped has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 09, 2012, by Hamm, Volker. This opposition was filed on patent number EP05108086A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP04787096A Jan, 2016 Page White & Farrer Limited Patent maintained as amended
EP05108086A Feb, 2012 Hamm, Volker The patent has been limited


US patents provide insights into the exclusivity only within the United States, but Edurant Ped is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Edurant Ped's family patents as well as insights into ongoing legal events on those patents.

Edurant Ped's family patents

Edurant Ped has patent protection in a total of 44 countries. It's US patent count contributes only to 13.5% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Edurant Ped.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Edurant Ped's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 23, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Edurant Ped Generics:

There are no approved generic versions for Edurant Ped as of now.





About Edurant Ped

Edurant Ped is a drug owned by Janssen Products Lp. Edurant Ped uses Rilpivirine Hydrochloride as an active ingredient. Edurant Ped was launched by Janssen Prods in 2024.

Market Authorisation Date:

Edurant Ped was approved by FDA for market use on 15 March, 2024.

Active Ingredient:

Edurant Ped uses Rilpivirine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Rilpivirine Hydrochloride ingredient

Dosage:

Edurant Ped is available in tablet, for suspension form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 2.5MG BASE TABLET, FOR SUSPENSION Prescription ORAL